INDP Filing Forensics: +114% Close-to-Close in 4 Days on a $1.20 to $2.57 Run

TLDR

• INDP surged +114.2% close-to-close in four trading days ($1.20 → $2.57, September 4 to September 10, 2026) on Pharmaceuticals-sector volume expansion. The specific operational catalyst was not identified in available press releases — the only flagged news items were a cluster of 8-K filings (September 1 and September 10) and the Q2 2026 update (August 13). The tradeable float is 38,590,000 shares (38.59M).
• Market cap sits at $150,800,000 with an enterprise value of $142,700,000, short interest of just 0.2%, and institutional ownership of 0.3% — a thin, retail-driven structure.
• Cash position is $8,200,000 with roughly 5.5 months of runway against a quarterly burn of $-4,470,000. This company is cash-constrained, which is precisely why the filing chain below matters.
• The run was primed by a loaded dilution stack: two fresh S-3 shelves (June 26 and August 17), an effectiveness clearance (August 26), two 424B5 pricing supplements (August 31 and September 4), and an active $100,000,000 ATM opened August 2026.
• A $10,000 position held across the close-to-close move would have returned $21,417 (+114.2%). The single best full-session grab — the September 8 open-to-close leg — returned +43.2%.

What Actually Drove INDP's +114% Run?

INDP climbed +114.2% close-to-close between September 4 ($1.20) and September 10 ($2.57) while a fully loaded shelf-and-ATM structure sat active behind it. This is a forensic filing story, not a catalyst story — the news corpus surfaced only 8-K filings and a Q2 corporate update, not an FDA action, contract, or partnership. For a sub-$160M Pharmaceuticals name on Nasdaq with a 38.59M float, the tell was in the SEC filings, not the headlines.

Indaptus Therapeutics is an Israel-domiciled clinical-stage pharmaceutical company. Small-cap earnings are not a catalyst here — the August 13 Q2 report landed with a whisper (that session closed at $1.84 only on September 8, weeks later). What reprices a name like this is the dilution plumbing: when does the shelf go effective, when does the 424B5 price the raise, and how much ATM capacity is hanging over the tape. All of that is public, timestamped, and was readable days before the move.

The move ran on a 38.59M float with 0.2% short interest. This was not a short squeeze. It was a thin-float repricing on top of an actively refreshed registration stack — the kind of setup that shows up in SEC Filings before it shows up on a chart.

INDP also led last week's small-cap tape. In the September 3–September 10 window, it printed the top runner slot in the Pharmaceuticals sector, which contributed 3 of the week's 20 runners that gained 50% or more. For context on how a filing chain front-runs this kind of move, our WCT filing forensics breakdown walks the same playbook on a different name.

The INDP Filing Timeline: S-3 to 424B5 to the Run

The sequence that matters is the classic offering chain — shelf registration (S-3) clears effectiveness, then a 424B5 pricing supplement makes the raise live. INDP filed 0 total filings in the last 90 days, and the ones that primed the tape cluster tightly around the run. Here is the chronological walk-through.

The chain reads cleanly: an S-3 on June 26 and August 17 loaded the capacity, the August 26 effectiveness notice and 424B3 cleared the path, and the two 424B5 pricing supplements on August 31 and September 4 made the offering live while the stock sat at $1.20. The run began September 8 (+43.2% regular session) — after the raise was priced. That is the single most important forensic observation in this post: the tape expanded after the 424B5s, not before.

For the anatomy of a shelf read ahead of a move, see our IPST shelf forensics post, which tracks the same S-3-to-run progression.

How the Filings Change INDP's Share Structure

INDP carries 14 active dilution facilities and 6 completed ones — and only the active set is a live overhang. Conflating a fully-converted note or a closed shelf with current dilution risk is the most common rookie mistake in reading these structures.

The active stack, straight from the facility data:

The headline number: a $100,000,000 ATM opened August 2026 via H.C. Wainwright. Against a $150,800,000 market cap, that single facility represents roughly 66% of the company's entire market value in potential share issuance. Add the $4,869,272 on the older June 2022 ATM and $18,250,000 of equity-line capacity, and the at-the-market firepower is substantial relative to an 8.2-million-dollar cash balance.

The warrants are where the price action intersects the structure. Four facilities carry a $1.75 strike, together representing roughly 6,000 warrants. At the September 10 close of $2.57, every one of those is in the money by $0.82. Exercised in full, that is about 1.58M new shares, roughly 4.1% of the 38.59M float. The July 2021 Merger PIPE warrants sit at a $308.00 post-split-adjusted strike — deeply out of the money and irrelevant to current supply. The two December 2025 convertible preferred tranches carry a $0.05 conversion price; the exact share count is not available in the data, but a five-cent conversion reference against a $2.57 print is a meaningful structural overhang to flag.

The completed / historical facilities are not current threats and should be read as raises that already happened: the September 2025 ATM, the January 2020 and May 2020 warrants, the September 2022 and March 2019 shelves, and — critically — the June 2025 convertible note, which is fully converted with $0 remaining. That note's dilution already occurred; citing it as live overhang would be a factual error.

Price Action Context: Before, During, and After the Filings

INDP was a dead tape until September 8, then expanded violently on rising volume. The pre-run base was mechanical — eight straight sessions under 350K shares — before the 424B5 window flipped the switch.

The volume regime change tells the whole story: from 129,913 shares on September 4 to 8,445,053 shares on September 8 — roughly 65x in one session. Total volume across the four-day runner window was 17,375,623 shares, with the peak single-day print of 8,445,053 on the breakout. The September 10 regular session opened $2.00 and closed $2.57 (+28.5%) on the same day an 8-K hit the tape. Pre-market and after-hours were comparatively calm — the September 10 pre-market opened $2.16 and faded to $1.98, while the after-hours session opened $2.54 and closed $2.56 — so the entire move lived in regular hours.

The Opportunity and the Risk: Trading a Live Offering

A stock with a live 424B5 and a $100M ATM is both the most dangerous and the most tradeable setup in small caps — and INDP is the textbook case. The risk and the opportunity come from the same fact: the company can sell shares into strength at any time.

The risk side is explicit. Cash is $8,200,000 against a $-4,470,000 quarterly burn — roughly 5.5 months of runway. A cash-constrained biotech with an open ATM and an effective shelf has every incentive to sell into a volume spike. The August 2026 ATM alone can absorb $100,000,000 of issuance, and the equity line adds $18,250,000 more. A trader buying the September 10 close at $2.57 is buying directly into the window where at-the-market sales are most attractive to the issuer — that is the definition of buying into dilution.

The opportunity side is the pre-offering and into-offering run. Market makers and issuers frequently let a thin float expand before and during an at-the-market program, because selling into $2.57 is far better for the balance sheet than selling into $1.20. That dynamic is exactly what the September 8–10 tape shows: the raise was priced via 424B5 on August 31 and September 4, and the stock then ran +114.2% on a 65x volume expansion. Fast traders who caught the September 8 breakout ($1.28 open) or the September 10 open ($2.00) rode the mechanical supply-into-strength leg.

The profit math, on a $10,000 base: holding the full close-to-close move from the September 4 open at $1.20 to the September 10 close at $2.57 returned $21,417 (+114.2%) — a gain of $11,417. The cleaner single-session trade, the September 8 regular-hours leg from $1.28 to $1.84, returned +43.2% ($14,375). The September 10 open-to-close grab from $2.00 to $2.57 returned +28.5% ($12,850). None of these required predicting a catalyst — they required reading that a cash-constrained name had just priced a raise and was expanding on volume.

The $1.75 warrant strike is the structural level to respect on the way up: above $1.75, 1,583,658 warrants are in the money and become a potential supply source. That does not cap the stock, but it marks where additional float can appear.

How to Find These Setups on SNACS

You find an INDP-style setup by screening for cash-constrained names with a freshly priced offering and a volume spike — all of which live in the scanner and the SEC research tool. Here is the exact workflow.

Start in the SEC research tool. Use the Filing Browser to pull 424B5 pricing supplements and S-3 shelf registrations, then sort by date. In the past 3 days, 6 companies filed 8 424B5 pricing supplements (WXM, LEU, AXGN, FCNCN, NTHI, and PAVM) and 4 filed new S-3 registrations (including KROS and SAFX). Each one is a candidate offering chain. Open the Dilution Snapshot to see active facility counts, shares at risk, and the lowest exercise price — for INDP that surfaces the $100M ATM and the $1.75 warrant strike instantly. The AI Chat lets you ask "what is the active dilution capacity and cash runway?" in plain language.

Then move to the SNACS scanner. Set a price filter of $1.00–$5.00, a float filter under 50M, and turn on the Dilution Alerts column plus the Cash Runway column. Sort by RVOL descending to surface names expanding on volume — INDP's jump from 129,913 to 8,445,053 shares would have lit up the RVOL filter on September 8. Click any ticker to open the ticker details page, which shows the chart, the dilution-risk panel (active shelf/ATM/warrant facilities), recent filings, and news in one view — no context switch.

Save the scan and wire it to a Dynamic Watchlist so any name matching "low runway + live offering + rising RVOL" auto-populates in real time; matched tickers show a colored square in the main stream. In the AI Playbook Builder, build a multi-step setup — historical base → 424B5 priced → volume trigger → entry → exit — and the live-matching engine will drop a star indicator on any scanner ticker that completes the pattern. Finally, log every attempt in the trading journal: its AI Insights flag your MFE capture rate and best time-of-day, so you learn whether you are actually catching the offering-run leg or chasing the exhaustion candle.

For the broader market context behind last week's runner-heavy tape, the September 10 weekly playbook and our filing forensics on DAIC both show how these setups repeat week to week.

Market Backdrop: A Defensive Tape

The macro call this week is Risk-Off / Consolidation, and INDP ran against that grain. The S&P 500 (SPY) closed at $757.83, -2.8% from its 52-week high of $779.37 and within 5% of the high, down -1.0% over 5 days and -1.9% over 20 days. The Nasdaq 100 (QQQ) closed at $708.69, -5.3% off its high, down -2.1% over 20 days. The Russell 2000 (IWM) — the small-cap tell — closed at $287.70, -5.7% from its 52-week high of $305.18 and down -5.0% over 20 days, the weakest of the four proxies. The Dow Jones Industrial (DIA) closed at $520.75. With small caps lagging, single-name setups like INDP carry more failure risk; tighter stops and reduced size are the appropriate adjustment in a defensive backdrop.

Sector-wise, capital rotated hard into Communication Services (RVOL 0.69 → 8.60, +1143%), Textile (+1010%), and Industrials (+504%) week-over-week. Pharmaceuticals was not among the rotating-in leaders, which reinforces that INDP's move was name-specific and filing-driven rather than a sector wave.

What to Watch Next

The forward question on INDP is whether the $100,000,000 ATM gets drawn against the volume it just created. Watch SEC Filings for a follow-up 8-K disclosing ATM sales or a new 424B5 — that would confirm the issuer sold into the strength and typically marks the end of the supply-into-strength leg. Watch the $1.75 warrant strike as a supply reference and the $8,200,000 cash balance as the reason the pressure to raise is real. In a Risk-Off tape with the Russell 2000 (IWM) down -5.0% over 20 days, continuation on a thin-float name is the exception, not the rule — so treat any further upside as a trade to manage, not a position to marry.

FAQ

What does a 424B5 filing mean for a stock like INDP?

A 424B5 is a pricing supplement that makes a shelf offering live — it confirms the company can sell registered shares immediately. INDP filed two 424B5s (August 31 and September 4, 2026), meaning the offering was priced and active while the stock sat near $1.20. For traders, a 424B5 is the signal that dilution is no longer theoretical; it is happening, and the issuer has a direct incentive to sell into strength.

Was INDP's +114% move a short squeeze?

No. INDP's short interest was only 0.2% and institutional ownership 0.3%, so there was no meaningful short base to squeeze. The +114.2% close-to-close move from $1.20 to $2.57 ran on a 38.59M float with volume expanding from 129,913 shares on September 4 to 8,445,053 on September 8 — a thin-float repricing on top of an active offering stack, not a covering event.

How do I check SEC filings for dilution risk before a stock runs?

Use the SEC research tool's Dilution Snapshot to see active facility counts, shares at risk, and the lowest exercise price, then read the filing chain in order: an S-3 shelf loads capacity, an effectiveness notice clears it, and a 424B5 makes the raise live. For INDP, that chain ran S-3 (June 26, August 17) → effectiveness (August 26) → 424B5 (August 31, September 4) — all readable days before the September 8 breakout.

What is an ATM offering and why does INDP's $100M ATM matter?

An ATM (at-the-market) offering lets a company sell new shares directly into the open market at prevailing prices, diluting holders without a fixed offering price. INDP's August 2026 ATM via H.C. Wainwright has $100,000,000 remaining — roughly 66% of its $150,800,000 market cap — so the issuer can absorb large volume spikes by selling into them, which is both the risk and the source of the pre-offering run.

Which INDP dilution facilities are actually a current threat?

Only the 14 active facilities are live overhang: the $100M and $4.87M ATMs, the $18.25M equity line, the four $1.75-strike warrant tranches (1,583,658 warrants total), and the two December 2025 convertible preferred tranches at a $0.05 conversion price. The 6 completed facilities — including the June 2025 convertible note, which is fully converted with $0 remaining — are historical raises, not current dilution risk.

How much could a trader have made on INDP's run?

A $10,000 position held from the September 4 open at $1.20 to the September 10 close at $2.57 returned $21,417 (+114.2%), a gain of $11,417. The single best full-session leg was September 8, where the regular-hours move from $1.28 to $1.84 returned +43.2% ($14,375 on the same base). The September 10 open-to-close grab from $2.00 to $2.57 returned +28.5%.

Should I trust small-cap earnings as a catalyst for a name like INDP?

No. Small-cap and clinical-stage biotech earnings rarely move the stock — INDP's Q2 2026 report landed August 13 with no reaction, and the run did not start until September 8. The real catalysts for names like this are SEC filings (offerings, S-3 shelves, ATMs), FDA actions, contract wins, and unusual volume. For INDP specifically, the offering chain and the 65x volume expansion were the tells, not the financials.

How can I get alerted to setups like INDP automatically?

Save a scanner filter for low cash runway, float under 50M, and rising RVOL, then link it to a Dynamic Watchlist so matching names auto-populate in real time and show a colored square in the main stream. In the Playbook Builder, define the offering-run pattern (priced 424B5 → volume trigger → entry) and the live-matching engine drops a star indicator on any ticker that completes it — so you see the setup forming instead of finding it after the move.